Catalog No.
Product Name
Application
Product Information
Citations
-
Endogenous Metabolite
Letimide hydrochloride is an endogenous metabolite with potent analgesic activity. In vitro studies have demonstrated its cytogenetic effects on human lymphocytes, while in vivo assessments in mouse bone marrow cells have shown no significant chromosomal aberrations or sister chromatid exchanges. Additionally, teratogenic studies in mice indicate that Letimide hydrochloride does not induce congenital malformations, supporting its safety profile for research applications in pain management and genetic stability. -
Endogenous Metabolite
(8Z,14Z)-Eicosadienoic acid is an endogenous metabolite classified as an ω-8 C20:2 fatty acid. It has been detected in human milk, corresponding to 0.19% of total fatty acids. This compound can be converted in vivo by desaturases into eicosatrienoic acids, which are known for their potent vasodilatory effects. The specific physiological effects of (8Z,14Z)-eicosadienoic acid remain to be fully explored, making it a valuable candidate for further research into its biological roles and potential therapeutic applications. -
Endogenous Metabolite
D-Fructose 6-phosphate dipotassium is an endogenous metabolite that primarily targets metabolic pathways related to cell growth and autophagy. It plays a crucial role as an intermediate in glycolysis and the pentose phosphate pathway, and it is hydrolyzed by fructose-1,6-bisphosphatase. This compound can also be converted into D-glucose 6-phosphate by phosphoglucose isomerase, making it relevant in studies of metabolic disorders, including Lewy body dementia. Researchers can utilize D-Fructose 6-phosphate dipotassium to explore cellular metabolism and related pathological conditions. -
Leukotriene
14,15-Leukotriene D4 (14,15-LTD4) is a leukotriene synthesized from arachidonic acid via the 15-lipoxygenase-1 pathway in eosinophils. It exhibits potent biological activity in mediating inflammatory responses and is implicated in various respiratory conditions, including asthma and allergic reactions. This compound serves as a valuable tool for research applications focusing on leukotriene signaling and related inflammatory pathways. -
Endogenous Metabolite
Fexaramate is a selective agonist of the farnesoid X receptor (FXR), an endogenous metabolite involved in bile acid homeostasis and lipid metabolism. This compound plays a crucial role in regulating glucose and lipid levels, making it valuable for research into metabolic disorders, liver diseases, and therapeutic interventions targeting FXR signaling pathways. Its specific action on FXR enhances understanding of its physiological functions and potential therapeutic applications. -
Endogenous Metabolite
Promothiocin A is a thiopeptide that acts as an inducer of the tipA promoter. This compound is derived from the bacterium Streptomyces sp. SF2741 and functions as an endogenous metabolite, playing a pivotal role in gene regulation. Its ability to modulate bacterial gene expression makes Promothiocin A a valuable reagent for research applications in microbiology and molecular biology, particularly in studies focused on transcriptional control mechanisms. -
Endogenous Metabolite
A-57696 is a cholecystokinin (CCK) antagonist that selectively targets cortical CCK-B receptors with an IC50 of 25 nM. It functions as a competitive antagonist, effectively reversing CCK8-induced pancreatic alpha-amylase secretion and phosphatidylinositol degradation, while also inhibiting CCK8-induced gallbladder contraction. Notably, A-57696 exhibits partial agonist activity at CCK-B/gastrin receptors on NCI-H345 cells, eliciting up to 80% of the maximal CCK8 response. This compound serves as a valuable tool in research focused on gastrointestinal physiology and the modulation of CCK-related pathways. -
Fungal Metabolite
Fellutanine A is a diketopiperazine alkaloid that serves as a fungal metabolite derived from Penicillium fellutanum. This compound exhibits significant biological activity, demonstrating potential antifungal properties. It can be utilized in research focused on studying fungal physiology and the development of antifungal agents. -
HMG-CoA Reductase Inhibitor
(Rac)-5-Keto Fluvastatin is a specific impurity of Fluvastatin, functioning primarily as an HMG-CoA reductase inhibitor. With an IC50 value of 8 nM, it demonstrates potent inhibitory activity against this key enzyme involved in cholesterol biosynthesis. This compound is useful for studies focused on lipid metabolism and cardiovascular research, enabling the investigation of statin-related mechanisms and effects. -
HMG-CoA Inhibitor
L-669,262 is a potent inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, exhibiting an IC50 of 0.10 ng/mL in rat liver preparations. This compound effectively downregulates cholesterol synthesis, making it a valuable tool in lipid metabolism research and studies focused on cardiovascular disease. Its specificity and high potency facilitate a wide range of applications in pharmacological studies and drug development targeting dyslipidemia. -
HMG-CoA Reductase Inhibitor
Pitavastatin magnesium is a potent HMG-CoA reductase inhibitor that plays a critical role in lipid metabolism. It effectively reduces total cholesterol and low-density lipoprotein cholesterol levels, as demonstrated in hyperlipidemic rat models. This compound is valuable for research focused on cardiovascular and cerebrovascular diseases, particularly in studies investigating hyperlipidemia and its associated conditions. -
HMG-CoA Reductase (HMGCR) Inhibitor
L 668411 is a β-lactone compound that acts as an inhibitor of HMG-CoA Reductase (HMGCR), targeting cholesterol biosynthesis. It effectively inhibits rat liver cytosolic 3-hydroxy-3-methylglutaryl-CoA synthase and reduces [14C] acetate incorporation into sterols in Hep G2 cell cultures. The inhibition demonstrates an irreversible mechanism in cellular systems, while exhibiting reversible properties in cultured cells and animal models, making it a valuable tool for studying cholesterol metabolism and related diseases. -
HMG-CoA Reductase Inhibitor
Tenivastatin calcium is an HMG-CoA reductase inhibitor that effectively lowers cholesterol levels by inhibiting the rate-limiting step in cholesterol biosynthesis. This compound has potential applications in the study of hyperlipidemia and cardiovascular disease, providing insights into lipid metabolism and associated disorders. Researchers can utilize Tenivastatin calcium to explore therapeutic strategies aimed at managing lipid abnormalities. -
HMG-CoA Reductase Inhibitor
Glenvastatin is a potent inhibitor of HMG-CoA reductase, an enzyme critical in the cholesterol biosynthesis pathway. This compound effectively reduces plasma levels of total cholesterol and phospholipids, as well as liver cholesterol content, without increasing cholesterol or total bile acids in gallbladder bile. Glenvastatin is valuable for research focused on hyperlipidemia and related metabolic disorders. -
HMG-CoA Reductase Inhibitor
(3S,5R)-Fluvastatin-d6 sodium is a deuterium-labeled derivative of the HMG-CoA reductase inhibitor, (3S,5R)-Fluvastatin. This compound exhibits a potent inhibitory activity with an IC50 of 8 nM, making it valuable for studying cholesterol biosynthesis. In addition to its role in lipid regulation, Fluvastatin has been shown to protect vascular smooth muscle cells from oxidative stress via the Nrf2-dependent antioxidant pathway, offering insights for cardiovascular research applications. -
HMG-CoA Reductase Inhibitor
Dalvastatin is a potent inhibitor of HMG-CoA reductase, a key enzyme involved in cholesterol biosynthesis. By effectively reducing cholesterol levels, Dalvastatin demonstrates significant potential in the management of hyperlipidemia and related cardiovascular conditions. Its ability to modulate lipid profiles makes it a valuable tool for research into lipid metabolism and cardiovascular disease therapeutics. -
HMG-CoA Reductase Inhibitor
GR 92549 is a potent, orally active inhibitor of HMG-CoA reductase, targeting the enzyme responsible for cholesterol biosynthesis. This compound effectively reduces cholesterol levels and may serve as a significant tool in metabolic and cardiovascular research. Its capability to modulate cholesterol metabolism makes it valuable for studies related to dyslipidemia and atherosclerosis. -
HMG-CoA Reductase (HMGCR) Control
((3R,5R,E)-7-(4-(4-fluorophenyl)-6-isopropyl-2-(N-methylmethylsulfonamido)pyrimidin-5-yl)-3,5-dihydroxyhept-6-enoate) calcium(II) is a control compound associated with HMG-CoA reductase (HMGCR), a key enzyme involved in cholesterol biosynthesis. This compound serves as an impurity marker in the analysis of Rosuvastatin, an established HMGCR inhibitor. Its role in research applications includes evaluating batch consistency and the purity of statin formulations, facilitating the development and quality control of lipid-lowering therapeutics. -
HMG-CoA Reductase (HMGCR) Inhibitor
Rawsonol is a potent inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, a key enzyme in the cholesterol biosynthesis pathway. Derived from the green alga Avrainuika rawsoni, Rawsonol demonstrates significant inhibitory activity, making it a valuable tool for research investigating cholesterol regulation and related metabolic pathways. Its role as an HMGCR inhibitor positions it for applications in studies of lipid metabolism and cardiovascular health. -
HMG-CoA Reductase Inhibitor
(3S,5R)-Pitavastatin calcium functions primarily as an inhibitor of HMG-CoA reductase, a key enzyme in cholesterol biosynthesis. This enantiomer exhibits significant lipid-lowering activity, making it valuable for research into dyslipidemia and cardiovascular disease. Its efficacy in modulating lipid profiles has led to its application in studies focused on metabolic disorders and therapeutic approaches for hypercholesterolemia. -
Herbicide Agent/4-HPPD Inhibitor
Benzobicyclon is an effective 4-hydroxyphenylpyruvate dioxygenase (4-HPPD) inhibitor exhibiting herbicidal properties. It hydrolyzes in the presence of water to produce the active agent benzobicycline, leading to the bleaching and subsequent death of various weed species. This reagent demonstrates efficacy against grass, sedge, and broadleaf weeds, including biotypes that are resistant to sulfonylurea herbicides, making it a valuable tool for herbicide resistance research and weed management studies. -
HPPD/PPO Dual Inhibitor
HPPD/PPO-IN-1 is a dual inhibitor targeting 4-hydroxyphenylpyruvate dioxygenase (HPPD) and protoporphyrinogen oxidase (PPO), exhibiting IC50 values of 0.12 μM and 0.51 μM, respectively, for Arabidopsis thaliana HPPD and Nicotiana tabacum PPO. This compound demonstrates broad-spectrum herbicidal activity against various weed species while maintaining safety for crops such as peanuts and cotton. HPPD/PPO-IN-1 is suitable for research focused on the development of environmentally sustainable herbicides. -
IDO1 Inhibitor
Amg-1 is a potent and reversible inhibitor of indoleamine 2,3-dioxygenase 1 (IDO1), with an IC50 value of 3.0 μM. It demonstrates significant selectivity, with over 80-fold greater inhibition of IDO1 compared to IDO2 and over 20-fold selectivity against TDO. This compound is valuable for research in cancer, hypotension, and neurological disorders, facilitating the exploration of therapeutic strategies targeting immune regulation and metabolism. -
Apo-IDO1 Inhibitor
IDO1-IN-28 is an Apo-IDO1 inhibitor that disrupts heme binding with an IC50 of 1.29 μM. This compound selectively targets apo-IDO1, offering a valuable tool for studying its role in tumor immunology. IDO1-IN-28 is applicable in cancer research, facilitating investigations into the modulation of immune responses in various malignancies. -
IDO Inhibitor
(S)-Indoximod is a selective inhibitor of indoleamine 2,3-dioxygenase (IDO), with a Ki value of 19 μM. This compound has demonstrated notable biological activity in modulating immune responses and has potential applications in cancer research and the study of neurological disorders. Its ability to inhibit IDO activity makes it a valuable tool for investigating therapeutic strategies in various disease contexts. -
IDO1/TDO Inhibitor
IDO1/TDO-IN-4 is a dual inhibitor targeting indoleamine 2,3-dioxygenase 1 (IDO1) and tryptophan 2,3-dioxygenase (TDO), exhibiting IC50 values of 3.53 μM and 1.15 μM, respectively. It interacts with IDO1 through hydrogen bonding and engages TDO via π−π stacking interactions. This compound is valuable for investigating the role of IDO1/TDO in depression and related conditions, including infectious, metabolic, and autoimmune disorders. -
IDO1 Inhibitor
DP00477 is a potent inhibitor of indoleamine 2,3-dioxygenase 1 (IDO1), exhibiting an IC50 value of 7.0 µM. This compound is valuable for investigating the role of IDO1 in tumor immune evasion and has potential applications in cancer research. Its inhibitory effects can facilitate studies on the modulation of the immune response in cancer therapy. -
IDO1 Inhibitor
IDO1-IN-18 is a potent inhibitor of indoleamine 2,3-dioxygenase 1 (IDO1), a critical enzyme in tryptophan metabolism that plays a role in immune regulation and tumor immune evasion. This compound demonstrates significant biological activity in inhibiting IDO1, which may enhance anti-tumor immune responses. IDO1-IN-18 is valuable for research applications in cancer biology and immunology, particularly in studies exploring the modulation of immune responses in tumor microenvironments. -
IDO1/IDO2 Inhibitor
IDO1/2-IN-1 is a novel dual inhibitor targeting indoleamine 2,3-dioxygenase 1 (IDO1) and IDO2, with IC50 values of 28 nM and 144 nM, respectively. This compound demonstrates significant antitumor activity, making it a valuable tool for cancer research. The orally active nature of IDO1/2-IN-1 enhances its potential for in vivo studies, facilitating the exploration of immunomodulatory effects and therapeutic applications in oncology. -
IDO1/TDO Inhibitor
IDO1/TDO-IN-9 is a potent dual inhibitor targeting indoleamine 2,3-dioxygenase 1 (IDO1) and tryptophan 2,3-dioxygenase (TDO), exhibiting IC50 values of less than 1 μM. This compound effectively inhibits the enzymatic activity of IDO1 and TDO, thereby blocking the degradation of tryptophan to kynurenine. By restoring immune activity within the tumor microenvironment, IDO1/TDO-IN-9 shows potential in suppressing tumor growth, making it a valuable tool for cancer research. -
IDO1 Inhibitor
4-Phenyl-1H-1,2,3-triazole is a potent inhibitor of indoleamine 2,3-dioxygenase 1 (IDO1), with an IC50 value of 60 μM. This compound plays a crucial role in cancer research by modulating immune responses and inhibiting tumor-induced immune tolerance. Its ability to interfere with the kynurenine pathway makes it a valuable tool for studying tumor microenvironments and exploring new therapeutic strategies in oncology. -
IDO1 Inhibitor
BMS-986242 is a selective, orally active inhibitor of indoleamine-2,3-dioxygenase 1 (IDO1). This compound demonstrates potent inhibition of IDO1 enzymatic activity, a critical pathway in the immunosuppressive tumor microenvironment. Research applications include exploring its use in combination therapies for cancer treatment and investigating its effects on immune response modulation. -
IDO Inhibitor
IDO2-IN-1 is a potent inhibitor of Indoleamine 2,3-dioxygenase 2 (IDO2), exhibiting an IC50 value of 112 nM. This compound is designed for use in research related to inflammatory autoimmunity, providing valuable insights into the mechanisms of immune modulation. Its ability to selectively inhibit IDO2 activity positions it as a crucial tool for exploring therapeutic strategies in related disease contexts. -
IDO Inhibitor
Kushenol E is a flavonoid derived from Sophora flavescens and acts as a non-competitive inhibitor of indoleamine 2,3-dioxygenase 1 (IDO1), with an IC50 of 7.7 µM and a Ki of 9.5 µM. This compound exhibits notable anti-tumor activity, making it relevant for research applications in cancer biology and immunotherapy. Its mechanism of action provides potential insights into immune modulation within the tumor microenvironment. -
IDO Inhibitor
IDO-IN-18 is a potent inhibitor of indoleamine 2,3-dioxygenase (IDO), an enzyme involved in the regulation of immune responses. By inhibiting IDO, this compound enhances T-cell activity and potentially mitigates immunosuppression in the context of infectious and cancer diseases. IDO-IN-18 is instrumental in research aimed at understanding immune modulation and developing therapeutic strategies for various malignancies and chronic infections. -
IDO1 Inhibitor
(S)-LY-3381916 is a selective inhibitor of Indoleamine 2,3-Dioxygenase 1 (IDO1), demonstrating potent activity with an IC50 value of less than 1.5 µM. This S-isomer effectively binds to the apo-IDO1 form, targeting the enzyme in its unbound state and circumventing the heme-bound variant. Research applications include investigating the role of IDO1 in immunoregulation and exploring therapeutic strategies in cancer and inflammatory diseases. -
IDO1 Inhibitor
(Rac)-LY-3381916 is a potent inhibitor of Indoleamine 2,3-Dioxygenase 1 (IDO1), specifically targeting its apo- form. This racemic compound demonstrates selective inhibition of IDO1 activity and is capable of penetrating the blood-brain barrier. Its unique mechanism of action makes it valuable for research applications focused on immunotherapy and neurological diseases where modulation of the kynurenine pathway is critical. -
IDO1 Inhibitor
IDO-IN-8 is a selective inhibitor of indoleamine 2,3-dioxygenase 1 (IDO1), with an IC50 range of 1-10 μM. This compound is derived from patent WO2012142237A1 and is utilized in research to elucidate the role of IDO1 in immune regulation and tumor microenvironments. IDO-IN-8 is particularly relevant in studies focused on cancer immunotherapy and the modulation of immune responses. -
IDO1 PROTAC Degrader
NU227326 is a potent IDO1 PROTAC degrader designed to penetrate the blood-brain barrier, exhibiting a DC50 of 4.5 nM in HiBiT degradation assays. It effectively degrades IDO1 in human glioblastoma cell lines U87 and GBM43, with DC50 values of 7.1 nM and 11.8 nM, respectively, as demonstrated in Western blot assays. This compound is valuable for research into various malignancies, including glioblastoma, prostate cancer, triple-negative breast cancer, pancreatic cancer, and ovarian cancer. -
IDO1 Inhibitor
BMT-297376 is a potent inhibitor of Indoleamine 2,3-dioxygenase 1 (IDO1), an enzyme implicated in the modulation of immune responses and tumor microenvironments. This compound has shown significant biological activity by effectively blocking IDO1, which can enhance anti-tumor immunity and alleviate immune evasion in various cancer models. BMT-297376 is a valuable tool for researchers investigating immune modulation and the therapeutic potential of IDO1 inhibition in oncology. -
PROTAC IDO1 Degrader
NU223612 is a selective PROTAC designed to target and degrade indoleamine 2,3-dioxygenase 1 (IDO1) through CRBN-mediated proteasomal degradation, exhibiting a Kd of 640 nM. With a binding affinity for CRBN of 290 nM, NU223612 effectively reduces IDO1 protein levels, making it a valuable tool in the study of immune modulation and tumor microenvironments. Additionally, NU223612 demonstrates the ability to cross the blood-brain barrier, enhancing its potential utility in neurobiological research. -
IDO1 Inhibitor
IDO-IN-6 (NLG-1486) is a potent inhibitor of indoleamine 2,3-dioxygenase (IDO1), demonstrating an IC50 of less than 1 μM. This compound plays a critical role in modulating immune responses by inhibiting tryptophan catabolism, making it a valuable tool in cancer immunotherapy and research on immune regulation. IDO-IN-6 is extensively utilized in studies investigating tumor microenvironments and the effects of IDO1 inhibition on immune system activity. -
IDO Inhibitor
IDO1-IN-11 is a potent inhibitor of indoleamine 2,3-dioxygenase 1 (IDO1) with an IC50 value of 0.6 nM. This compound exhibits significant activity in modulating immune responses by inhibiting tryptophan catabolism, thereby enhancing T cell function. IDO1-IN-11 is valuable for research applications investigating cancer immunotherapy and immune regulation. -
IDO1 Inhibitor
IDO1-IN-7 is a potent and selective inhibitor of indoleamine-2,3-dioxygenase-1 (IDO1), exhibiting an IC50 of 6.1 nM in cellular assays using SKOV3 cancer cells. This compound modulates immune responses, making it a valuable tool for investigating immunotherapeutic strategies in cancer research. IDO1-IN-7 is suitable for studies aimed at understanding the role of IDO1 in tumor immune evasion and identifying potential therapeutic interventions. -
IDO1/IDO2 Inhibitor
IDO1/2-IN-1 hydrochloride is a potent dual inhibitor of indoleamine 2,3-dioxygenase 1 (IDO1) and indoleamine 2,3-dioxygenase 2 (IDO2), with IC50 values of 28 nM and 144 nM, respectively. This compound demonstrates significant antitumor activity, making it a valuable tool for cancer research. Its oral bioavailability facilitates its use in various biological studies aimed at understanding immune modulation and tumor microenvironment interactions. -
IDO1 Inhibitor
NUCC-0223619 is an IDO1 inhibitor that induces degradation of the indoleamine 2,3-dioxygenase 1 (IDO1) protein. This compound serves as a valuable tool for studying the immunomodulatory effects of IDO1 inhibition and is applicable in further research, including the synthesis of PROTACs (PROteolysis TArgeting Chimeras). Researchers can utilize NUCC-0223619 to investigate its potential impact on tumor microenvironments and immune responses. -
IDO1 Inhibitor
IDO1-IN-17 is a selective inhibitor of the enzyme indoleamine 2,3-dioxygenase 1 (IDO1), exhibiting an IC50 of 0.44 μM in HeLa cells. By blocking IDO1, this compound modulates the kynurenine pathway and impairs tryptophan catabolism, leading to enhanced immune response. IDO1-IN-17 is a valuable tool for research into cancer immunotherapy and the exploration of immune metabolism. -
IDO1/TDO Inhibitor
IDO1/TDO-IN-3 is a potent inhibitor targeting both indoleamine 2,3-dioxygenase 1 (IDO1) and tryptophan 2,3-dioxygenase (TDO). It demonstrates significant inhibitory potency with IC50 values of 0.005 μM for IDO1 and 0.004 μM for TDO. This compound exhibits considerable anti-tumor activity in vivo while displaying no apparent toxicity, making it a valuable tool for studies in cancer immunotherapy and metabolism. -
IDO Inhibitor
IDO-IN-15 is a potent inhibitor of indoleamine 2,3-dioxygenase 1 (IDO1), with an IC50 value of less than 0.51 nM. This compound is utilized in research focused on cancer immunity, neurodegenerative diseases, and inflammation due to its ability to modulate the immune response by inhibiting tryptophan catabolism. Its high specificity and efficacy make it a valuable tool for investigating the therapeutic potential of targeting IDO1 in various biological contexts. -
IDO1 Inhibitor
MMG-0358 is a potent inhibitor of indoleamine 2,3-dioxygenase 1 (IDO1), exhibiting an IC50 of 2 nM in cellular assays against murine IDO1 (mIDO1) and 80 nM against human IDO1 (hIDO1). Additionally, it displays IC50 values of 330 nM and 71 nM in enzymatic assays of hIDO1 at pH 6.5 and pH 7.4, respectively. This compound is a valuable tool for studying immune regulation and may have applications in cancer immunotherapy and related research fields.
